The flags with the logos of the Danish drug manufacturer Novo Nordisk, manufacturer of the successful diabetes and the weight loss treatments Ozempic and Wogovy are images, while the company presents the annual report in Novo Nordisk in Bagvaerd, Denmark, on February 525.
Mads Claus Rasmussen | AFP | Getty images
Novo Nordisk It obtained a great legal victory that largely restricts the marketing compound pharmacies or the sale of cheaper and unveiled versions of the successful medicine to lose weight of the Ozempic drug addict.
A federal judge in Texas at the end of Thorsday rejected an offer to aggravate pharmacies to continue making copies of Ozempic and Wogovy, while a legal challenge about the shortage of those drugs develops. That came in response to a February demand from a commercial group composed against the determination of the food and medicines administration that the active ingredient in those drugs, Semaglutide, is no longer in the USS.
The patients mass the cheapest imitators when Ozempic and Wogovy were scarce during the last two years due to the demand triggered, or if they did not have insurance coverage for expensive treatments.
FDA statement shortage duration, pharmacists can legally make versions composed of brand notes. Many Telesalud companies, such as Hims and hersHe also offered those imitators. But medication manufacturers and some health experts have retreated against the practice that FDA does not collect compound medications, which are tailored copies essentially prescribed by a doctor to meet the needs of a specific patient.
“We are pleased that the court has rejected the attempts of the compounds of undermining the decision based on FDA data that the shortage or semagglutida is resolved, said Steve Benz, the corporate vice president, legal and the General Council of the United States of Novo Nordisk.
“Patient Safety Remains A Top Priority for Novo Nordisk and the Extensive Nationwide Legal Actions We have tasks to protect americans from the Health Risks posed by illegitimate ‘Semaglutide’ Drugs Are Working,” Hee Said, Pharsutse Pharsus and The Companacy And Companacy And COMPANACY AND COMPANACY AND COMPANACY AND COMPANACY AND COMPANACY AND COMPANACY AND COMPANACY AND COMPANACY AND THE COMPANY -LEGDING AND COMPANACY’S COMPANACY AND COMPANACY AND THE COMPANYA THE COMPANY AND THE COMPANY OF LAWNACY AND THE COMPANY OF THE COMPANY -LAWY AND THE COMPANY -Lawy, other entities in 32 states.
On Thursday, the United States District Judge, Mark Pittman, specifically denied that Outsourcing facilities associations offer for a preliminary court order that would have prevented the FDA from taking measures against its members for making semaglutide copies.
This decision defends the previous determination of the FDA that the scarcity of semaglutidas in the US. UU. It has ended and, badly, the FDA can now go immediately after the so -called 503A pharmacies that make composite versions for a Patcepide specification.
These pharmacies are largely regulated by states instead of the FDA.
The decision also means that the FDA can begin to go to Pharmacies 503B regulated by the federal government, which manufacture bulk compound medications with or without recipes, after May 22. The agency’s actions may include product senuras and warning letters to pharmacies.
Thursday’s decision follows another victory for Novo Nordisk. A different federal judge in Texas earlier this week failed in favor of the drug manufacturer against a 503A pharmacy, Pharmacy Mediak, permanently prohibiting the marketing business or sale of compound semaglutida.
Novo Nordisk and Eli Lilly They have taken energetic measures aggressively in compound pharmacies in the last two years, since they benefit from the popularity of their weight loss and their diabetes medications.
Eli Lilly has gone through a similar process with pullzepatido, the active ingredient in its zepbunda medication and treatment of Mounjaro diabetes. The FDA declared the shortage of the US Tirzepaturo about last year, which led to the same commercial group composed to sue the FDA for the drug.
In March, a federal judge denied the application of the group composed of a preliminary court order on the application of the FDA against its members for making copies of Mounjaro and Zepbound. The compound group has appealed.
